If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-18. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Xanomeline (developmental code name LY-246,708) is a small molecule muscarinic acetylcholine receptor agonist that was synthesized in a collaboration between Eli Lilly and Novo Nordisk as an investigational therapeutic being studied for the treatment of central nervous system (CNS) disorders. Its pharmacological action is mediated primarily through stimulation of central nervous system muscarinic M1 and M4 receptor subtypes. Xanomeline is a non-selective muscarinic acetylcholine receptor agonist with similar high affinity for all five muscarinic acetylcholine receptor subtypes but has greater agonistic activity at the M1 and M4 subtypes. Xanomeline/trospium (Cobenfy), is a combination medication used in the treatment of schizophrenia.
According to the new policy, Twitter verifies six different types of accounts; for three of them (companies, brands, and influential individuals like activists), the existence of a Wikipedia page will be one criterion for showing that the account has "Off Twitter Notability".
In June 2025, KFC temporarily closed all its 11 restaurants in Denmark and dismissed its franchise holder in the country, after a TV show (broadcast on June 23) revealed that in multiple restaurants, employees were systematically falsifying ("extending") use-by dates on raw chicken, and possibly other problems. Before broadcast, the questions by the TV reporter caused the national food authority to launch simultaneous inspection raids on all 11 restaurants. None got an all-clear, seven received strict warnings and four were given punishments (fines/charges or forced instant closure). Among the issues found by the authorities were moldy residue in multiple restaurants; a common procedure of reusing the breading mix continuously instead of using fresh breading mix every three hours, as stated in written procedures that were hastily changed during the raids (some inspections only saw the new procedure, which they found dubious); a common thawing procedure (with no written risk assessment documentation) for raw chicken which would allow chicken to be served up to four days after the start of defrosting and made it difficult to confirm the actual age of the raw chicken; and suspect messages between restaurant bosses and the national franchise holder about deceiving inspectors from both the government and KFC Western Europe.
For over fifty years, Padre Pio of Pietrelcina reported stigmata which were studied by several 20th-century physicians, whose independence from the Church is not known. The observations were reportedly inexplicable and the wounds never became infected. His wounds healed once, but reappeared. The wounds were examined by Luigi Romanelli, chief physician of the City Hospital of Barletta, for about one year. The physician Angelo Maria Merla noted that the wounds were not tubercular in origin but could not make an official diagnosis without further tests. The surgeon Giorgio Festa, a private practitioner, also examined them in 1920 and 1925. Professor Giuseppe Bastianelli, physician to Pope Benedict XV, examined the wounds, but no report of his examinations was made. Pathologist Amico Bignami of the University of Rome also observed the wounds, describing them as shallow. Festa, who had originally agreed with Bignami, later described the wounds as superficial when covered with a scab. Giorgio Festa noted that "at the edges of the lesions, the skin is perfectly normal and does not show any sign of edema, of penetration, or of redness, even when examined with a good magnifying glass". Alberto Caserta took X-rays of the hands in 1954 and found no abnormality in the bone structure. Giuseppe Sala who worked as a physician for Pio between 1956 and 1968 commented that tests revealed his blood had no signs of abnormality. There were both religious and non-religious critics who accused Padre Pio of faking his stigmata, saying he used carbolic acid to make the wounds.
Azurin is a small, periplasmic, bacterial blue copper protein found in Pseudomonas, Bordetella, or Alcaligenes bacteria. Azurin moderates single-electron transfer between enzymes associated with the cytochrome chain by undergoing oxidation-reduction between Cu(I) and Cu(II). Each monomer of an azurin tetramer has a molecular weight of approximately 14kDa, contains a single copper atom, is intensively blue, and has a fluorescence emission band centered at 308 nm. Azurins and pseudoazurins participate in the denitrification processes in bacteria., including the gram-negative bacteria Pseudomonas aeruginosa, by interacting with cytochrome c551. Azurin from P aeruginosa is a type I blue copper protein (cupredoxin), while cytochrome c551 (9 kDa) is a haem-containing cytochrome. Azurin possesses a relatively large hydrophobic patch close to the active site, and two residues in this hydrophobic patch, Met-44 and Met-64, are believed to be involved in its interaction with the redox partners cytochrome c551 and nitrite reductase. Although unrelated to its electron-transfer property, azurin has been found to have anticancer properties through its interaction with tumor-suppressor protein p53.
Sources: en.wikipedia.org
Caesium-135 is a mildly radioactive isotope of caesium with a half-life of 1.33 million years. It decays via emission of a low-energy beta particle into the stable isotope barium-135. Caesium-135 is one of the seven long-lived fission products and the only alkaline one. In most types of nuclear reprocessing, it stays with the medium-lived fission products (including 137Cs which can only be separated from 135Cs via isotope separation) rather than with other long-lived fission products. As an exception, molten salt reactors create 135Cs as a completely separate stream outside the fuel (after the decay of bubble-separated 135Xe). The low decay energy, lack of gamma radiation, and long half-life of 135Cs make this isotope much less hazardous than 137Cs or 134Cs. Its precursor 135Xe has a high fission product yield (e.g., 6.3333% for 235U and thermal neutrons) but also has the highest known thermal neutron capture cross section of any nuclide. Because of this, much of the 135Xe produced in current thermal reactors (as much as >90% at steady-state full power) will be converted to practically stable 136Xe before it can decay to 135Cs despite the relatively short half-life of 135Xe. Little or no 135Xe will be destroyed by neutron capture after a reactor shutdown, or in a molten salt reactor that continuously removes xenon from its fuel, a fast neutron reactor, or a nuclear weapon.
== Chart == A pink background means that the element is significantly radioactive. Bismuth is not highlighted because its radioactivity is considered negligible here. (Bismuth is stable enough to be used for the production of cosmetics.)
== Aftermath == The newly elected Volkskammer was constituted on 5 April 1990, and elected Sabine Bergmann-Pohl of the CDU as its president. As the State Council of the GDR was dissolved at the same time, she became East Germany's interim head of state. Four days later, after protracted negotiations, Lothar de Maizière announced the formation of a grand coalition between the Alliance for Germany, SPD, and BFD. On 12 April 1990, he was elected Prime Minister of the GDR by the Volkskammer with 265 votes in favour, 108 against, and 9 abstentions. The new cabinet was also confirmed. The partners in the coalition commanded a two-thirds supermajority in the Volkskammer, making it an übergroß coalition with enough seats to pass amendments to the constitution. The new parliament quickly passed several pieces of major legislation, including a new law regarding local government on 17 May, a law ratifying the monetary, economic, and social union with the Federal Republic of Germany on 18 May (which became effective on 1 July), and constitutional amendments on 17 June. On 21 June, the Volkskammer formed a special committee, chaired by Joachim Gauck, to control the dissolution of the Ministry for State Security (Stasi). On 20 September 1990, the Volkskammer voted 299–80 to accept the Treaty on the Final Settlement with Respect to Germany, which had earlier been approved in a 442–47 vote by the West German Bundestag.
===== Light collector ===== Using graphene as a photoactive material requires its bandgap to be 1.4–1.9 eV. In 2010, single cell efficiencies of nanostructured graphene-based PVs of over 12% were achieved. According to P. Mukhopadhyay and R. K. Gupta organic photovoltaics could be "devices in which semiconducting graphene is used as the photoactive material and metallic graphene is used as the conductive electrodes". In 2008, chemical vapor deposition produced graphene sheets by depositing a graphene film made from methane gas on a nickel plate. A protective layer of thermoplastic is laid over the graphene layer and the nickel underneath is then dissolved in an acid bath. The final step is to attach the plastic-coated graphene to a flexible polymer sheet, which can then be incorporated into a PV cell. Graphene/polymer sheets range in size up to 150 square centimeters and can be used to create dense arrays. Silicon generates only one current-driving electron for each photon it absorbs, while graphene can produce multiple electrons. Solar cells made with graphene could offer 60% conversion efficiency.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.